Cover Image
市場調查報告書

EpiCast Report:多發性硬化症的流行病學預測

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 258690
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:多發性硬化症的流行病學預測 EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026
出版日期: 2017年11月01日 內容資訊: 英文 35 Pages
簡介

多發性硬化症(MS)在全球每年影響250萬人,是青壯年中最大的衰弱性神經疾病。調查對象10個國家整體病例數2014年估計為909,398件,至2024年預計增加到942,567件。

本報告提供多發性硬化症(MS)的風險因素及全球趨勢的相關調查,主要8個市場(美國、法國、德國、義大利、西班牙、英國、日本、加拿大)及新興市場(印度、中國)的資料。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 風險因素和共生病症
    • MS患者的家族持有MS發病的1%∼5%的風險
    • 女性MS發病的風險為2倍,可是男性預後不佳
    • 白種人(Caucasian)比其他人種/民族的MS風險高
    • 維他命D對MS的預防效果,可能與出生的地區、月份有關聯
    • 環境暴露的時機影響MS風險
    • 被動吸煙有可能增加MS風險,讓預後惡化
    • 自體免疫疾病可能成為MS的共生病症
    • 精神性共生病症在MS患者中最大60%,有可能影響復發率
  • 全球趨勢
    • 北美
    • 歐洲
    • 亞洲
  • 預測手法
    • 利用來源
    • 未利用的來源
    • 預測的前提條件、手法
  • 多發性硬化症的流行病學預測
    • 患病數
    • 患病數:各年齡
    • 患病數:性別
    • 發病數
    • 發病數:各年齡
    • 發病數:性別
    • 多發性硬化症的亞型
  • 考察
    • 流行病學趨勢的結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

  • 參考資料
  • 關於作者
  • 關於GlobalData
  • 關於EpiCast
  • 免責聲明

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER168-17

Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, tremor, muscle spasm, prolonged double vision, slurred speech, and balance problems. It can occur at any age, but commonly affects people of ages 15-60 years. Women are about twice as likely as men to develop this disease (Mayo Clinic, 2016). MS symptoms may occur and disappear completely, while the permanent neurological problems occur when the disease advances.

Our epidemiologists forecast that the diagnosed prevalent cases of MS in the 7MM will grow by an Annual Growth Rate (AGR) of almost 0.8% per year over the next 10 years, from around 1 million cases in 2016 to around 1.1 million cases in 2026. Of the 7MM, the US had the highest number of diagnosed prevalent cases with around 0.4 million cases in 2016, while Japan had the lowest number of diagnosed prevalent cases with almost 20,000 cases in 2016. In 2016, the US accounted for around 40% of all the diagnosed prevalent cases of MS, while Japan accounted for only about 2% of diagnosed prevalent cases of MS in the 7MM.

Our epidemiologists forecast that the diagnosed incident cases of MS in the 7MM will grow by an AGR of around 0.3% per year over the next 10 years, from around 49,000 cases in 2016 to just over 50,000 cases in 2026. Additionally, the US will have the highest AGR of almost 0.8%, while Italy will have the lowest at negative rate of around 0.5%. From the 7MM, the US had the highest number of diagnosed incident cases of MS with over 20,000 cases in 2016, while Japan had the lowest number of diagnosed incident cases of MS with nearly 1,000 cases in 2016. In 2016, the US accounted for over 42% of all the MS cases, while Japan accounted for only about 2% of diagnosed incident cases of MS in the 7MM.

The report "EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends for MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of MS, segmented by sex and by age (for all ages) in these markets. The diagnosed prevalent cases are further segmented by types of MS (relapsing-remitting [RRMS], primary progressive [PPMS], and secondary progressive [SPMS]) in the 7MM.

Scope

  • The Multiple sclerosis (MS) EpiCast Report provides an overview of the risk factors and global trends for MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of MS, segmented by sex and by age (for all ages) in these markets. The diagnosed prevalent cases are further segmented by types of MS (relapsing-remitting [RRMS], primary progressive [PPMS], and secondary progressive [SPMS]) in the 7MM.
  • The MS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The MS EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global MS market.
  • Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MS therapeutics in each of the markets covered.
  • Understand magnitude of MS population by disease type.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 3
  • 1.2 List of Figures 3

2 Multiple Sclerosis Executive Summary 4

  • 2.1 Related Reports 6
  • 2.2 Upcoming Reports 6

3 Epidemiology 7

  • 3.1 Disease Background 7
  • 3.2 Risk Factors and Comorbidities 7
  • 3.3 Global and Historical Trends 8
  • 3.4 Forecast Methodology 10
    • 3.4.1 Sources 10
    • 3.4.2 Forecast Assumptions and Methods 13
    • 3.4.3 Diagnosed Prevalent Cases of MS 14
    • 3.4.4 Diagnosed Prevalent Cases of MS by Types 17
    • 3.4.5 Diagnosed Incident Cases of MS 19
  • 3.5 Epidemiological Forecast for MS (2016-2026) 21
    • 3.5.1 Diagnosed Prevalent Cases of MS 21
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of MS 22
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of MS 22
    • 3.5.4 Diagnosed Prevalent Cases of MS by Types 23
    • 3.5.5 Diagnosed Incident Cases of MS 24
    • 3.5.6 Age-Specific Diagnosed Incident Cases of MS 25
    • 3.5.7 Sex-Specific Diagnosed Incident Cases of MS 26
  • 3.6 Discussion 27
    • 3.6.1 Epidemiological Forecast Insight 27
    • 3.6.2 Limitation of Analysis 28
    • 3.6.3 Strengths of Analysis 29

4 Appendix 30

  • 4.1 Bibliography 30
  • 4.2 About the Authors 32
    • 4.2.1 Epidemiologist 32
    • 4.2.2 Reviewers 33
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 33
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 34
  • 4.3 About GlobalData 35
  • 4.4 Contact Us 35
  • 4.5 Disclaimer 35

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for MS 8
  • Table 2: 7MM, Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, Selected Years 2016-2026 21
  • Table 3: 7MM, Diagnosed Incident Cases of MS, Both Sexes, All Ages, Selected Years 2016-2026 25

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of MS, Both Sexes, All Ages,2016 and 2026 5
  • Figure 2: 7MM, Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016 and 2026 6
  • Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of MS (%), Both Sexes, All Ages, 2016 9
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of MS (Cases per 100,000 Population), Both Sexes, All Ages, 2016 10
  • Figure 5: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of MS 11
  • Figure 6: 7MM, Sources Used and Not Used, Diagnosed Incident Cases of MS 12
  • Figure 7: 7MM, Sources Used and Not Used for the Diagnosed Prevalent Cases of MS by Types 13
  • Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, 2016 22
  • Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of MS, Both Sexes, All Ages, 2016 23
  • Figure 10: 7MM, Diagnosed Prevalent Cases of MS by Types, Both Sexes, All Ages, 2016 24
  • Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016 26
  • Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of MS, Both Sexes, All Ages, 2016 27
Back to Top